Author: Healthcare Propulsion Staff

Tumor suppressor genes are often viewed as the body’s built-in defense system against cancer. They produce proteins that help maintain and repair DNA, reducing the chances that harmful mutations will accumulate. When these genes stop working properly or are present at low levels, cancer risk can rise. But new research suggests that having too much of one DNA repair protein can also be a problem. Researchers at Penn State College of Medicine found that excessive activity of the gene EXO1 can damage DNA rather than protect it. Instead of repairing genetic material, too much EXO1 can break down DNA and…

The popularity of GLP-1 medications such as semaglutide (Ozempic, Wegovy, and Rybelsus) and tirzepatide (Mounjaro and Zepbound) has dramatically reshaped the way obesity is treated. However, specialists say these drugs are only one piece of the puzzle when it comes to managing one of the most widespread chronic health conditions in the United States. A new commentary in the American Gastroenterological Association journal Gastroenterology revisits the influential POWER (Practice Guide on Obesity and Weight Management, Education, and Resources) framework, originally introduced in 2017. Titled “Revisiting POWER in the GLP-1 Age,” the update reflects major developments in obesity care, from the…